para-aminosalicylic acid

Selective inhibition of vitamin B12 absorption by para-aminosalicylic acid.

Para-aminosalicylic acid (PAS) is not teratogenic among rats or rabbits (394).

Moreover, high dose para-aminosalicylic acid (4-ASA) was, for many years, used in the treatment of tuberculosis yet nephrotoxic reactions were uncommon.

Second-choice medicines include streptomycin, capreomycin, ethionamide, kanamycin, ofloxacin, para-aminosalicylic acid, and rifabutin.

Tell your health care provider if you are taking any medicines that may affect test results, including colchicine, neomycin (Neosporin), para-aminosalicylic acid, and phenytoin (Dilantin).

Like many commercially significant compounds, PAS has many names including para-aminosalicylic acid, p-aminosalicylic acid, 4-ASA, and simply P.

But in 1939 it was still very much the case: the discovery of the chemotherapeutic agents, rifampin, para-aminosalicylic acid, isoniazid and especially streptomycin, still lay far beyond a distant horizon.

These advances were furthered by implementing new TB treatment protocols that substituted physical activity for bed rest and; prescribed a combined drug therapy using streptomycin, INH, and para-Aminosalicylic acid.

Aminosalicylic acid (para-aminosalicylic acid, PAS, Paser): Aminosalicylic acid can reduce oral vitamin B absorption, possibly by as much as 55%, as part of a general malabsorption syndrome.

By 1944, para-aminosalicylic acid appeared as promising as streptomycin in initial trials, but because medical professionals in Sweden disparaged the new drug, Lehmann and his colleagues had to solicit charitable donations to subsidize the clinical trials that would ultimately prove its efficacy.